EGFR-TKI治疗肺腺癌的疗效与血清肿瘤标志物的相关性

doi:10.3971/j.issn.1000-8578.2012.05.006

EGFR-TKI治疗肺腺癌的疗效与血清肿瘤标志物的相关性

Correlations between EGFR Tyrosine Kinase Inhibitor and Serum Level of Tumor Marker in Lung Adenocarcinoma

摘要

摘要: 目的探讨表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)对肺腺癌的疗效和血清肿瘤标志物间的关系。方法回顾分析48例应用EGFR-TKI治疗的晚期肺腺癌患者的临床特征、生存时间和治疗前血清肿瘤标志物水平的相关性。结果 EGFR-TKI治疗后有效率为58.3%，控制率为65.6%；中位生存时间为13.2月。统计学分析显示:吸烟史、血清CEA和CA19-9水平与EGFR-TKI的疗效相关(P<0.05)；治疗前血清CEA，CA19-9水平高者有着更高的治疗有效率、控制率和更长的生存期(P<0.05)。结论 EGFR -TKI治疗前血清CA19-9和CEA的水平对预测EGFR-TRI对肺腺癌患者的疗效有参考价值。

Abstract: Objective To investigate the relationship between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) treatment effects and serum tumor markers in lung adenocarcinoma. Methods Forty-eight patients with advanced lung adenocarcinoma were treated with EGFR-TKI.The clinical features,survival time and the level of serum tumor markers for the patients before and after treatment were retrospectively analyzed. Results After EGFR-TKI treatment,the RR was 58.3% and DCR was 65.6% in lung adenocarcinoma;and median survival time was 13.2 months.Responses correlated significantly with smoking history and level of CEA or CA19-9 in serum(P<0.05).Patients with higher level of serum CEA and CA19-9 had higher disease control rate and longer survival(P<0.05). Conclusion Serum CA19-9 or CEA level can predict the response of EGFR-TKI to lung adenocarcinoma.

HTML全文

参考文献(13)

施引文献

资源附件(0)